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ABSTRACT
The degree and type of T cell infiltration influence rectal cancer prognosis regardless of classical tumor staging.
We asked whether clonal expansion and tumor infiltration are restricted to selected-phenotype T cells; which
clones are accessible in peripheral blood; and what the spatial distribution of their target antigens is.
From five rectal cancer patients, we isolated paired tumor-infiltrating T cells (TILs) and T cells from
unaffected rectum mucosa (TUM) using 13-parameter FACS single cell index sorting. TCRαβ sequences,
cytokine, and transcription factor expression were determined with single cell sequencing. TILs and TUM
occupied distinct phenotype compartments and clonal expansion predominantly occurred within CD8+
T cells. Expanded TIL clones identified by paired TCRαβ sequencing and exclusively detectable in the tumor
showed characteristic PD-1 and TIM-3 expression. TCRβ repertoire sequencing identified 49 out of 149
expanded TIL clones circulating in peripheral blood and 41 (84%) of these were PD-1− TIM-3−. To determine
whether clonal expansion of predominantly tumor-infiltrating T cell clones was driven by antigens uniquely
presented in tumor tissue, selected TCRs were reconstructed and incubated with cells isolated from
corresponding tumor or unaffected mucosa. The majority of clones exclusively detected in the tumor
recognized antigen at both sites.
In summary, rectal cancer is infiltrated with expanded distinct-phenotype T cell clones that either
i) predominantly infiltrate the tumor, ii) predominantly infiltrate the unaffectedmucosa, or iii) overlap between
tumor, unaffected mucosa, and peripheral blood. However, the target antigens of predominantly tumor-
infiltrating TIL clones do not appear to be restricted to tumor tissue.
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Introduction
The incidence of colorectal cancer ranks fourth in men and
third in women among all cancer entities and the five year
survival rate is approximately 64% for all stages combined.1
Among a variety of prognostic parameters, the type and
density of tumor-infiltrating T cells (TILs) have been shown
to affect clinical outcomes and overall survival independent of
classical tumor-node-metastasis (TNM) staging.2–7
T cell function is determined by T cell receptor (TCR) speci-
ficity and the expression patterns of characteristic transcription
factors and cytokines.8–12 Depending on their differentiation
state, T cells can contribute to recognition and elimination of
(foreign) antigens, autoimmunity, induction of tolerance, and
effective B cell responses. T cell-mediated tumor control relies
on the integration of antigen-dependent mechanisms (T cell
specificity) and mechanisms that are not directly antigen-
dependent (immune checkpoints, microenvironment).
According to current understanding, the role of TILs
includes the recognition and killing of tumor cells based on
their presentation of mutation-derived neo-antigens. In fact,
subsets of T cells from colorectal cancer patients have been
shown to recognize neo-antigens. Patients with microsatellite
instability, who can be expected to harbor high mutational
loads, have increased numbers of TILs and better clinical
outcomes.13,14 Furthermore, the therapeutic success of adop-
tively transferred in vitro-expanded neo-antigen-specific
T cells highlights their outstanding role in cancer control.15
In addition to neo-antigens, certain unmutated self-antigens
have been shown to induce tumor-directed T cell responses
even across different patients.16
T cell function is critically dependent on co-stimulatory
and co-inhibitory signals. Expression of immune checkpoint
molecules (PD-1 and TIM-3 among others) on colorectal
cancer-infiltrating T cells suggests an exhausted immune
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phenotype interfering with anti-tumor T cell function.17
However, treatment of colorectal cancer with antibodies
against PD-1 or its ligand PD-L1 has not been effective to
date except in patients with a high mutational
burden.13,14,18,19
Defining the functions of different phenotype TILs and the
spatial distribution of their target antigens is critical for under-
standing the composition of immune cells in the cancer-
associated microenvironment and for the design of novel
immunotherapies. We asked whether clonal expansion and
tumor infiltration are restricted to selected phenotype and speci-
ficity T cells, and which clones are accessible in the peripheral
blood of rectal cancer patients. To minimize phenotype diversity
due to location-dependent molecular and clinical features in
colorectal cancer,20,21 we restricted the study to rectal cancer
patients. Our technologies for single cell phenotyping and TCR
sequencing22–24 comparatively defined clonal expansion-
associated immune phenotypes of T cells from cancer tissue and
adjacent unaffected mucosa from five treatment-naïve patients at
the single cell level. The identified clones were tracked in the
peripheral blood of the same patients at the time of surgical
tumor removal and one follow-up visit using multi-parameter
flow cytometry, TCRβ repertoire and single cell sequencing.25
Selected T cell clones were recombinantly expressed26 and incu-
bated with cells isolated from tumor and unaffectedmucosa of the
same patients to determine the spatial distribution of the corre-
sponding target antigens (Figure 1 for study specimens and
workflow).
Results
Tumor infiltration is associated with characteristic T cell
immune phenotypes
Rectal cancer shapes its microenvironment by attracting and
re-programming selected types of (immune) cells, supporting
tolerance and immune evasion. We hypothesized that
immune phenotypes of tumor-infiltrating T cells (TILs)
would be substantially different from T cells infiltrating the
adjacent unaffected mucosa (TUM).
Multi-parameter flow cytometry (FACS) was used to define
T cell immune phenotypes fromTILs and TUM, isolated in parallel
from surgical specimens of five treatment-naïve rectal cancer
patients (Figure 1, Table 1). The FACS panel included 13 markers
for the identification of major states of T cell differentiation and
selected immune checkpoint molecules (Suppl. Table 1). Using
t-stochastic neighbor embedding (t-SNE), we could identify phe-
notype compartments occupied by i) TILs, ii) TUM, and iii) T cells
with phenotype characteristics overlapping between both sites
(Figure 2(a)). Although the degree of phenotype overlap varied
between individual patients, these three compartments were con-
sistently identified in all patients (Suppl. Figure 1). CD8+ T cell
phenotypes were especially distinct between TILs and TUM
(Figure 2). While CD38 and PD-1 were expressed on significantly
more CD8+ TILs when compared to TUM, B- and T-lymphocyte
attenuator (BTLA) was expressed at higher frequencies on CD8+
TUM (Figure 2(b,c)). The immune checkpoint molecule TIM-3,
and CD57, a marker associated with exhausted-phenotype T cells,
were also enriched on TILs compared to TUM, although this
finding did not reach statistical significance.
Clonal expansion predominantly occurs in T cells with
distinct immune phenotypes
Previous studies have reported clonal expansion of CD4+ and
CD8+ TILs in colorectal cancer.16,22,27 We asked whether
clonal T cell expansion was associated with particular immune
phenotypes and applied our technology for single cell paired
TCRαβ and phenotype sequencing in combination with 13-
parameter FACS index sorting24 to four selected rectal cancer
patients. Randomly selected single TCRαβ+ TILs and TUM
were index-sorted for single cell phenotyping and sequencing
(Figure 3(a), Suppl. Figures 2 and 3). Clonal expansion was
defined as the detection of at least two T cells with identical
TCRαβ complementarity-determining region (CDR)-3 amino
acid sequences. Numbers of expanded clones were not sig-
nificantly different between TILs and TUM (Figure 3(b)).
Independent of tissue location, expanded T cell clones were
predominantly CD8+ (134 of 149 TIL clones and 85 of 105
Figure 1. Study specimens and workflow. The distance between the tumor margin and the specimen of unaffected mucosa tissue was > 4 cm for all cases but varied
between patients. PBMC: peripheral blood mononuclear cells, TILs: tumor-infiltrating T cells, TUM: T cells from unaffected mucosa, TCR: T cell receptor, d: day after
surgery.
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TUM clones) (Figure 3(c)). Clonally expanded TILs could be
distinguished by phenotype from clonally expanded TUM
(Figure 3(d), Suppl. Figure 4), as clonally expanded TILs
were significantly more frequently CD38+, PD-1+, and TIM-
3+ (Figure 3(e)). IFNG, PRF1, and GZMB expression was
significantly different between clonally expanded and non-
expanded T cells (Suppl. Figure 5) and followed the same
patterns in TILs and TUM. Notably, the transcription factor
FOXP3 was predominantly expressed in non-expanded TILs
(Figure 3(a,f)).
Selectively tumor-infiltrating T cell clones express the
checkpoint molecules TIM-3 and PD-1 and rarely circulate
in peripheral blood
We asked whether subsets of clonally expanded TILs were pre-
ferentially detectable in the tumor, whether they overlapped with
adjacent unaffected mucosa or peripheral blood, and to what
extent circulation in peripheral blood was affected by complete
tumor removal. Peripheral blood mononuclear cells (PBMCs)
were isolated from each patient at the day of surgery and at one
follow-up visit (day 46–106 after surgery, Figure 1). Bulk CD8+
and CD8− T cells were FACS-sorted (on average 5.8 × 105 and
1.2 × 106 cells per patient respectively, Suppl. Table 2, Suppl. Fig.
6) and their TCRβ repertoires were sequenced using deep
sequencing. As prior experiments had shown that clonal T cell
expansion in TILs and TUM predominantly occurred in the
CD8+ compartment (Figure 3(c)), we focused on CD8+ periph-
eral blood T cells for repertoire sequencing.
We detected on average 962 (range 343–2,244) individual
CD8+ T cell clones per time point and patient by peripheral
blood TCRβ repertoire sequencing (Suppl. Table 2). TCR
sequences from single TILs, TUM, and the corresponding periph-
eral blood showed substantial clonal overlap within individual
patients but not a single TCR overlapped between different
patients (Figure 4(a)). From a total of 149 expanded TIL clones,
29 (19.5%) were detectable in the unaffected mucosa and 49
(32.9%) in the peripheral blood, whereas 92 (61.7 %) were exclu-
sively detectable among TILs (Figure 4(a,b)). Predominantly
tumor-infiltrating clones expressed PD-1 and TIM-3 (42.6%
and 21.2% of the clones respectively), whereas TIL clones that
overlapped with unaffected mucosa and/or peripheral blood were
PD-1− TIM-3− (Figure 4(c)). When focusing on the TIL clones
detectable in the peripheral blood, PD-1 and TIM-3 expression
was mostly absent (84% of the clones, Figure 4(d)).
The accurate determination of clonal overlap between TILs
and TUM relies on the stability of immune phenotypes over
time and the detection limit of our sequencing assays.
The immune phenotypes of peripheral blood CD8+ T cells,
in particular CD38, integrin beta-7, and CD45RA expression,
were substantially different from TILs (Figure 4(e)), albeit stable
over time as shown for CD4 and CD45RA as examples (Figure 4
(f)). PD-1 and TIM-3 expression was enriched on clones selec-
tively infiltrating the tumor (Figure 4(c)) and rare in peripheral
blood (<1.4% and <6.6% of CD8+ T cells for PD-1 and TIM-3,
respectively, Figure 4(e)). To focus on these rare populations,
we specifically sorted single peripheral blood T cells with
increased PD-1 or TIM-3 expression (184 cells per population
and patient, Suppl. Fig. 7) and sequenced their TCRs using
single cell sequencing (Suppl. Tab. 3). Clones were determined
to be absent in the peripheral blood if they could not be detected
by TCRβ repertoire or single cell sequencing (Figure 4(a,b)).
The dominantly expanded CD8+ T cell clones in the peripheral
blood were stable across different time points and clones with
a frequency of >0.2% in peripheral blood at the day of surgery
(day 0) were consistently detectable in the follow-up samples
(Figure 4(g)) regardless of surgical tumor removal. This suggests
that cues other than tumor neo-antigens are likely to be the
drivers of their expansion.
Expanded T cell clones, irrespective of their origins,
recognize antigens present in corresponding tumor and
unaffected mucosa tissues
PD-1+ TIM-3+ expanded T cell clones predominantly infil-
trated the tumor. We asked whether the presentation of
antigens driving clonal expansion of predominantly tumor-
infiltrating T cells was restricted to tumor tissue.
Based on their frequencies, we chose four T cell clones
exclusively detected in the tumor and three clones over-
lapping between tumor, unaffected mucosa, and peripheral
blood (Figure 5(a), Table 2). Their TCRs were reconstructed
and functionally expressed on 58α−β− T hybridoma cells
that had previously been transfected with GFP under the
control of nuclear factor of activated T cells (NFAT)26 and
human CD8αβ chains.28 GFP expression and mouse IL-2
Table 1. Patient characteristics.
Pt Sex Age (years) Histology Tumor stage MSI HLA class 1 Clinical follow-up
1 f 80 Moderately differentiated adenocarcinoma pT3 pN2a (4/12) M0 G2 R0 L0 V0 No A* 02:01, 11:01
B* 08:01, 15:01
C* 03:04, 07:01
no follow-up data available
2 m 76 Mucinous adenocarcinoma pT3(m) pN0 (0/14) M0 R0 L0 V0 No A* 01:01, 68:01
B* 51:01, 52:01
C* 04:01, 12:02
alive +20 months, relapse-free
3 m 57 Moderately differentiated adenocarcinoma pT3 pN0 (0/13) M0 G2 R0 L0 V0 No A* 32:01, 33:01
B* 07:05, 40:06
C* 15:02, 15:05
alive +20 months, relapse-free
4 m 62 Moderately differentiated partially mucinous
(< 30%) adenocarcinoma
pT2 pN0 (0/16) M0 G2 R0 L0 V0 No A* 24:02, 26:01
B* 13:02, 18:01
C* 06:02, 07:01
no follow-up data available
5 m 77 Moderately differentiated adenocarcinoma pT2 pN0 (0/14) M0 G2 R0 L0 V0 No n.d. death +1 month
due to complication
Pt: patient, f: female, m: male, MSI: microsatellite instability, L0: no lymphatic vessel invasion, V0: no venous invasion, (m): multiple primary tumors in a single site, n.
d.: not determined
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production were detected as readouts for antigen-dependent
T cell activation. After stimulation with plate-bound anti-
mouse CD3 (positive control), the seven 58α−β− cell lines
expressing recombinant TCRs were on average 77% GFP+
and produced on average 8,613 pg/ml murine IL-2 (Suppl.
Fig. 8). To test whether target antigens were presented,
TCR-recombinant 58α−β− cells were co-incubated with left-
over cells isolated from tumor and unaffected mucosa
Figure 2. Subsets of TILs and TUM show distinct immune phenotypes. TILs and TUM pairs from five patients were stained in parallel with a multi-parameter FACS
panel. (a) t-SNE visualization distinguished TILs from TUM and identified immune phenotype compartments i) predominantly occupied by TILs, ii) predominantly
occupied by TUM, or iii) occupied by T cells from both locations. Each data point represents one single cell from patient 3 as an example. (b) Detailed immune
phenotypes of CD8+ TILs and CD8+ TUM from all n = 5 patients (n = 3 for TIM-3, n = 4 for CD28 and BTLA) determined by FACS were visualized as box plots.
* p < 0.05, Student’s t-test (c) shows detailed FACS plots for the parameters significantly differently expressed between TILs and TUM from patient 3 as an example.
Gates for CD38 and BTLA were set based on expression of the respective markers on TCRαβ− cells. PD-1 gates were adjusted to the 98th expression percentile on
TCRαβ− cells. All FACS plots were pre-gated on single live TCRαβ+ lymphocytes.
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Figure 3. Clonal expansion-associated phenotype patterns of TILs and TUM. (a) Parallel next generation sequencing of TCRαβ, transcription factor, and cytokine genes
from amplified cDNA of single TILs and TUM (Suppl. Figure 2 for sorting gates). The sequencing and FACS data of single cells are arranged in columns with each
column representing one single cell. The top bar indicates TCR sequences; adjacent columns with the same color in the top bar indicate single cells with identical
CDR3 amino acid sequences of their TCRαβ genes. Clonal expansion was defined as the detection of at least two cells with identical TCRαβ sequences. The lower part
of the heatmap is derived from the corresponding FACS index sort data and fluorescence intensities are color-coded from grey (lowest expression) to red (highest
expression) for the indicated parameters. The heatmap shows data from patient 1 as an example (see Suppl. Figure 3 for detailed data of all patients in the study). (b)
shows numbers of expanded T cell clones per patient. Each data point represents one patient (black, blue, red, green for patients 1, 2, 3, 4, respectively). (c) shows
CD8 expression on expanded T cell clones. (d) Single TCR-sequenced TILs and TUM from patient 1 as an example are visualized with t-SNE. Clonal expansion was
enriched in CD8+ compartments. (e) shows selected markers significantly differentially expressed between clonally expanded TILs and TUM. The left panel shows data
from all patients summarized as box plots. Each data point in the FACS plots (data from patient 1 as an example) represents one single cell belonging to an
expanded T cell clone. An individual clone was considered positive for a particular marker based on the majority of cells of the respective clone. Gates for CD38 were
set based on expression on TCRαβ− cells. TIM-3 and PD-1 gates were adjusted to the 98th expression percentile on TCRαβ− cells. (f) shows FOXP3 expression
determined by sequencing in non-expanded T cell clones. Box plots: The lower and upper hinges correspond to the 25th and 75th percentiles. The upper and lower
whiskers extend from the hinge to the largest or lowest values respectively, no further than 1.5 x inter-quartile range. Data beyond the end of the whiskers are
plotted individually.
*p < 0.05, **p < 0.01, Student’s t-test
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Figure 4. Clonal overlap between TILs and TUM is associated with characteristic immune phenotypes. The outer circle shows single cell TCRαβ sequencing data of TILs and TUM
from patients 1–4. Cells with the same TCRαβ CDR3 sequences are represented with the same color and cells are ordered by clone size. Grey represents single non-expanded
T cells. The inner circle indicates whether a particular T cell clone was detected in peripheral blood by TCRβ repertoire or single cell sequencing at any time point. Connectors
indicate clonal overlap between TILs and TUM (black if the clone was expanded within TILs, otherwise grey). (b) Absolute numbers of overlapping clones between clonally
expanded TILs, TUM (clonally expanded and non-expanded), and peripheral blood are shown in a Venn diagram for patients 1–4 combined. (c) The left panel shows the frequency
of PD-1 and/or TIM-3 expression on expanded TIL clones also detectable in peripheral blood and/or unaffectedmucosa for all patients combined. PD-1+ TIM-3+ summarizes cells
that were PD-1+ and/or TIM-3+. PD-1− TIM-3− cells were negative for bothmarkers. FACS plots show data frompatient 1 as an example. Each data point represents one single cell
of an expanded T cell clone. An individual clone was considered positive for a particular marker based on the majority of cells of the respective clone. PD-1 and TIM-3 gates were
adjusted to the 98th expression percentile on TCRαβ− cells. (d) shows the frequencies of PD-1 and/or TIM-3 expression on expanded TIL clones detectable in peripheral blood for
all patients combined. PD-1+ TIM-3+ summarizes cells thatwere PD-1+ and/or TIM-3+. PD-1− TIM-3− cells were negative for bothmarkers. (e) Paired TIL and peripheral blood FACS
phenotype data are visualized as box plots. The lower and upper hinges correspond to the 25th and 75th percentiles. The upper and lower whiskers extend from the hinge to the
largest or lowest values respectively, no further than 1.5 x inter-quartile range. Data beyond the end of the whiskers are plotted individually. TIL data are derived from all n = 5
patients (n = 3 for TIM-3, n= 4 for CD28 and BTLA) including n=4patients for peripheral blood phenotypes. (f) illustrates the consistency of peripheral blood immunephenotypes
over time. (g) shows frequencies of CD8+ peripheral blood T cell clones determined with TCRβ repertoire sequencing at the day of surgery (d0) and follow-up. The figure shows
the most expanded clones covering 80% of all sequencing reads per patient and time point. Each data point represents one out of 519 clones from all patients combined.
PB: peripheral blood; * p < 0.05, ** p < 0.01, *** p < 0.005, Student’s t-test
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tissues (Suppl. Tab. 4 for cell numbers). We detected neither
IL-2 production with ELISA nor GFP expression with FACS
significantly above background for any TCR-recombinant
cell line (Suppl. Fig. 9 as an example). However, by screen-
ing with fluorescence microscopy, we could observe single
cell aggregates containing GFP+ cells that could not be
Figure 5. Spatial presentation of target antigens of predominantly tumor-infiltrating expanded T cells. (a) shows the expansion of individual T cell clones only
detectable in the tumor or overlapping between tumor, unaffected mucosa, and peripheral blood. The figure shows data from all four patients combined and each
data point represents one clone. Clones selected for reconstruction and expression in 58α−β− cell lines were highlighted in red. CDR3 sequences and corresponding
patients for each reconstructed clone can be found in Table 2. (b–f) shows fluorescence microscopy of 58-1C10 (as an example for an expanded TCR only detectable
in TILs) unstimulated, stimulated with plate-bound anti-mouse CD3 (positive control), or after co-incubation with cells from the corresponding tumor, unaffected
mucosa tissue, or HLA-mismatched unaffected mucosa (negative control). Numbers in parentheses indicate absolute cell numbers for co-incubation. Fluorescence
microscopy was used to screen the entire co-incubation wells for GFP+ cells. (d–f) represent images of single GFP+ cells if any were detectable in the entire well. See
Supplementary Figure 10 for data from all re-expressed TCRs. For detailed cell numbers and culture conditions, see Supplementary Table 4.
Table 2. Spatial distribution and CDR3 amino acid sequences of T cell clones for re-expression on 58α−β− cells.
Detected in
TCR label Pt TRAV CDR3 alpha amino acid sequence TRAJ TRBV CDR3 beta amino acid sequence TRBJ TIL TUM PB
13B10 2 27*01 CAGGVNNNAGNMLTF 39*01 20–1*01 CSARDLRSTDTQYF 2–3*01 Yes Yes Yes
11B1 2 8–2*01 CAVSDVSGGYQKVTF 13*02 2*01 CASSGGRASGSGEQFF 2–1*01 Yes No No
11B7 2 39*01 CAAPIMEYGNKLVF 47*01 10–2*01 CASTPGLREKLFF 1–4*01 Yes No No
1C10 3 21*01 CAVTFPNAGNMLTF 39*01 6–6*01 CASSYGARLNTEAFF 1–1*01 Yes No No
1B4 4 13–1*01 CAVTGTASKLTF 44*01 29–1*01 CSVVGQDYEQYF 2–7*01 Yes No No
1A4-1 4 19*01 CALSEYGGSQGNLIF 42*01 6–1*01 CASSEASGSWTGELFF 2–2*01 Yes Yes Yes
1A4-2 4 1–2*01 CAVTDSNYQLIW 33*01 6–1*01 CASSEASGSWTGELFF 2–2*01 Yes Yes Yes
Pt: patient. PB: peripheral blood. TRAV: TCRα V-gene and allele. TRAJ: TCRα J-gene and allele. TRBV: TCRβ V-gene and allele. TRBJ: TCRβ J-gene and allele. TCR-
recombinant 58α−β− cell lines were named “58-TCR label”, e.g. “58-1C10”.
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detected with FACS due to their low frequencies (Figure 5
(b–f)). Of the four expanded TCRs exclusively detected in
tumor tissue (Figure 5(a)), one recognized antigen only
within cells isolated from the tumor (11B7), one recognized
antigen only within cells isolated from unaffected mucosa
(1B4), and two got activated by cells from both tumor and
unaffected mucosa (1C10 and 11B1, Figure 5(d,e) as an
example, Suppl. Fig. 10A for all re-expressed TCRs). From
the three expanded TCRs detectable in tumor, unaffected
mucosa, and peripheral blood, two were activated by cells
isolated from both tumor and unaffected mucosa (13B10,
1A4-1), and one got activated only by cells isolated from
unaffected mucosa (1A4-2, Suppl. Fig. 10B).
In conclusion, rectal cancer is infiltrated by expanded
T cell clones that either i) selectively infiltrate the tumor but
are functionally inhibited by the expression of immune check-
point molecules or ii) overlap between tumor, unaffected
mucosa, and peripheral blood, show distinct immune pheno-
types, and, at least the dominant clones, persist after surgical
tumor removal. The antigens underlying selective TIL expan-
sion do not appear to be exclusively presented in tumor tissue.
Discussion
A variety of cellular cancer treatment approaches including adop-
tive T cell transfer, chimeric antigen receptor (CAR) T cells,
immune checkpoint blockade, and bispecific antibodies depend
on efficient, targeted T cell functions. We addressed the following
questions at the single cell level: i) Which are the phenotypes and
presumed functional capacities of rectal cancer-infiltrating T cells,
ii) are particular immune phenotypes associated with predomi-
nant tumor infiltration, iii) which TIL clones are accessible in
peripheral blood, and iv) what is the spatial distribution of target
antigens of expanded TIL clones?
Data on detailed immune phenotypes of paired TILs and
TUM from the same patients are limited
5 and often disregard
the exact location of the tumor (different parts of the colon vs.
rectum). Studies addressing clonal T cell interrelatedness at
the single cell level are limited to single cases.16,22,29
Irrespective of clonal expansion, we identified tumor infiltra-
tion-associated T cell immune phenotypes. CD38+ and PD-1+
T cells were significantly enriched among TILs and we observed
similar trends for TIM-3 and CD57, though they did not reach
statistical significance. PD-1 and TIM-3 have previously been
shown to be expressed on colorectal cancer-infiltrating
T cells,17,30 however, PD-1-targeting therapies were particularly
effective in tumors with DNA mismatch-repair deficiencies.31
Notably, none of the patients in our study showed features of
microsatellite instability (Table 1). The role of BTLA, a receptor
involved in regulation of T cell function, has been under debate.
Depending on downstream signaling pathways, BTLAmay trans-
mit stimulatory or inhibitory signals possibly accounting for its
controversial roles in malignant melanoma, gastric, and gall blad-
der cancer.32–37 We show that BTLA was expressed on more than
50% of CD8+ T cells isolated from peripheral blood, tumor, and
unaffected mucosa although expression was less on TILs com-
pared to TUM. The functional and clinical significance of BTLA
expression on TILs and TUM in rectal cancer has to be determined
in future studies. Data on CD38 and CD57 expression on TILs in
comparison with TUM are limited but CD38 expression has been
shown to be induced by the tumor microenvironment and can
inhibit CD8+ T cell function via adenosine receptor signaling.38
Elevated numbers of CD57+ T and NK cells have been reported at
the invasive margins of colorectal cancer.3
Independent from the particular set of markers, which will
be subject to change depending on the selection of parameters
and sample size in future studies, we conclude that immune
phenotypes of TILs and TUM are substantially different.
Immune phenotypes and functions associated with clonal
T cell expansion can only be reliably studied at the single cell
level. To complement single cell paired TCRαβ sequencing,
additional TCRβ repertoire sequencing was chosen for selected
research questions. Tissue samples, especially from tumors and
unaffected mucosa, were limited and we were particularly
interested in clonal expansion-associated immune phenotypes.
Therefore, we applied single cell sequencing, which is superior
in terms of efficiency and the parallel determination of single
cell immune phenotypes. Surprisingly, numbers of expanded
clones were not significantly different between TILs and TUM.
While clonal TIL expansion could be tumor-specific/associated,
we assume the cues driving clonal TUM expansion not to be
directly tumor-related. This assumption is based on the major-
ity of expanded TUM clones not being detectable among TILs,
but a substantial amount overlapping with peripheral blood
and showing phenotype characteristics of functional, non-
exhausted T cells (PD-1− TIM-3−).
In sequencing several hundred single T cells per patient and
tissue type, there remains a chance of falsely determining clones
to be non-overlapping or non-expanded. However, the identi-
fied immune phenotypes were significantly associated with the
assigned status (overlapping vs. non-overlapping). In summary,
combined single cell flow cytometry and sequencing data suggest
the functional differentiation of clonally expanded TILs towards
tolerance in an antigen-specific fashion by the expression of
immune checkpoint and inhibitory molecules (PD-1, CD57,
CD38). FOXP3 expression in non-expanded TILs can be
assumed to support the tolerogenic microenvironment. Albeit
not clonally expanded, a substantial proportion of CD4+ TILs
were CD45RA−CCR7+CD28+ (Figure 3) characterizing them as
central memory T cells.39,40 Their partial expression of TGFB
and FOXP3 mostly in the absence of PRF1, GZMB, and IFNG
suggests tolerogenic differentiation. The clinical significance and
underlying differentiation mechanisms of these cells have to be
determined in future studies.
It is important to accurately identify TIL clones circulating in
the peripheral blood, as a variety of therapeutic approaches rely on
the accessibility of tumor-specific T cells in the peripheral blood.
Consistent with previous studies,41 expanded T cell clones in
peripheral blood remainedmostly stable over time and unchanged
months after tumor resection, suggesting that their expansion was
not driven by resected tumor-associated neo-antigens. Dominant
T cell clones in the peripheral blood of healthy individuals have
been considered specific for antigens of chronic infections such as
cytomegalovirus (CMV) or Epstein-Barr virus (EBV), among
others. In fact, one of the most expanded peripheral blood
TCRs in patient 1 (TCRβ CDR3 amino acid sequence:
CASSSANYGYTF), whichwas also expanded among this patient’s
TILs and TUM, has already been reported CMV-specific.
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As previously reported,17 particular phenotypes enriched in
TILs (PD-1+, TIM-3+) were rare in peripheral blood (Figure 4(d)),
however, especially PD-1+ peripheral blood T cells have pre-
viously been considered tumor-specific.15 To increase the chance
of detection, we extended our bulk sequencing data with high-
efficiency single cell TCRαβ sequencing of specifically sorted T cell
populations with increased PD-1 and TIM-3 expression.
A recent study suggests the distinction of exhausted-
phenotype, presumably tumor-specific, T cells and bystander
T cells in colorectal and lung cancer based on the expression
of the ecto-ATP/ADPase CD39.43 Selectively rectal cancer-
infiltrating T cells were exhausted and functionally inhibited,
as represented by PD-1, TIM-3, CD38, and CD57 expression.
By re-expressing selected TCRs in 58α−β− T hybridoma cell
lines and incubating them with cells isolated from their cor-
responding tissues, we showed that exhausted T cell clones
selectively expanded in tumor tissue could recognize antigens
presented on cells isolated from either site. The critical anti-
gens appeared to be presented on very few cells close to the
detection limit of our assays, which is not surprising since the
cell preparations were not enriched for any particular cell
type. Supplementary Figure 2 and microscopy (Figure 5)
show the majority of cells isolated from rectum tissue were
non-lymphocytes. In case a reconstructed TCR did not get
activated upon co-incubation, we cannot conclude whether
the lack of target antigen was due to the low frequency of
antigen-presenting cells or the target antigen indeed not being
presented in the investigated tissue. However, in vivo, parti-
cular expanded T cell clones selectively infiltrated the tumor
tissue and were below the detection limits of our technologies
at any other site, including peripheral blood. A variety of
mechanisms, such as chemo-attraction, selective antigen
accessibility in vivo, or inhibition of T cell expansion by
microenvironment-derived cues, among others, could account
for this observation. Recent studies on a variety of solid
cancers suggest antigens other than neo-antigens to drive
clonal TIL expansion in the tumor environment,16,43,44
which is in support of our findings. The clinical significance
of different phenotype TILs preferentially infiltrating tumor
tissue has to be determined along with TCR specificities in
future cohorts.
In conclusion, rectal cancer is infiltrated by clonally
expanded unique-specificity T cells that show dysfunctional/
exhausted immune phenotype patterns and rarely circulate in
the peripheral blood. Their target antigens, however, do not
seem to be exclusively presented in tumor tissue.
Patients and methods/materials and methods
Patients and sample preparation
Surgical specimens (one piece of rectal tumor and one piece of
unaffected recto-sigmoidal mucosa per patient) and heparin-
anticoagulated peripheral blood at surgery and one follow-up
time point were obtained from five treatment-naïve rectal cancer
patients. All patients gave written informed consent and the study
was approved by the local ethics committee (protocol EA1/007/
16 to L.H.). TILs and TUM were isolated from fresh specimens
immediately after surgery as previously described.22 In short,
tissue was cut into small pieces (2–4 mm3) and incubated in
PBS containing 10 mM Ethylendiaminetetraacetic acid (EDTA,
Invitrogen) for 30 min. Cells in suspension were passed through
a 100 μm cell strainer (Corning), tissue was incubated in
RPMI1640 containing 5% fetal bovine serum (FBS) and 0.5 mg/
ml collagenase (Serva, Collagenase NB 4) for 30 min. Finally, cells
were enriched through Percoll (GE Healthcare) gradient centri-
fugation and cryopreserved. Distances between the tumor and
unaffected mucosa specimens varied between patients but unaf-
fected mucosa samples were taken at least 4 cm apart from the
macroscopic tumor margin (Figure 1). PBMCs were isolated with
Ficoll-Paque PLUS (GE Healthcare) density gradient centrifuga-
tion. All cell preparations were cryopreserved in RPMI1640 con-
taining 50% FBS, 10% DMSO before further processing.
Fluorescence-activated cell sorting
Cells were thawed and stained with multicolor panels (Suppl.
Table 1). Antibodies were used according to the manufacturer’s
instructions. TILs and TUM samples from each patient were
processed in parallel to minimize instrument and staining varia-
bility. For single cell sequencing, single cells were index-sorted
directly into 96-well plates pre-filled with OneStep RT-PCR buffer
(Qiagen) as previously described.24 For TCRβ repertoire sequen-
cing, bulk cells were FACS-sorted into tubes prefilled with
RPMI1640 containing 2% FBS. DNA was isolated immediately
after sorting using the DNeasy Blood & Tissue Kit (Qiagen) and
stored at 4°C until further processing. All cells were sorted using
a FACSAria™ Fusion high-speed cell sorter (BD Biosciences)
equipped with a 70 µm nozzle.
Single cell sequencing and phenotyping
PCR amplification, library preparation, and MiSeq (Illumina)
sequencing were done as previously described.22,24
Sequencing data were processed as previously described24
and scripts can be downloaded from https://github.com/
HansmannLab/TRECA. Cytokines and transcription factors
were determined expressed in single cells if we detected
more than 10 reads for the respective cytokine or transcrip-
tion factor transcript.22 In case of the seven TCRs chosen for
re-expression (Figure 5), transcripts of the second TCRα
chain of TCR 1A4 were identified by manually screening the
sequencing output. No additional TCRα chains could be
identified for the remaining six re-expressed TCRs (Table 2).
Clonal expansion was defined as the detection of at least
two cells with identical TCRα and TCRβ amino acid
sequences. Index sorting assigned exact immune phenotypes
to every single sorted cell. Notably, some expanded clones
showed heterogeneous marker expression and a clone was
considered positive for a particular marker based on the
majority (> 50%) of cells with a particular TCR sequence.
TCRβ repertoire sequencing
TCRβ repertoire sequencing was done as previously described
and the read frequency cutoff for the definition of individual
clones was chosen at 10−4.25
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Recombinant T cell receptor expression in 58α−β− cell
lines and co-incubation with tumor and unaffected
mucosa cell preparations
Selected TCRs were reconstructed by completing the missing
leader, V, and constant region parts with sequences down-
loaded from IMGT,45 and expressed in 58α−β− cell lines as
previously described.26 58α−β− cell lines also expressed human
CD8αβ chains28 and GFP under the control of nuclear factor
of activated T cells (NFAT),26 so they light up green upon
activation. TCR-expression was confirmed by CD3 detection
with FACS. As positive controls, TCR-recombinant cell lines
were stimulated with plate-bound anti-mouse CD3 in 96-well
plates for 16 h. IL-2 was measured in cell culture supernatants
using the IL-2 Mouse Uncoated ELISA Kit (Thermo Fisher)
and GFP expression was detected with FACS and fluorescence
microscopy. For co-incubation experiments (Figure 5 and
Suppl. Figs. 9–10), TCR-recombinant 58α−β− cells were incu-
bated with cells isolated from i) corresponding tumor, ii)
corresponding unaffected mucosa tissue, or iii) tumor or
unaffected mucosa from an HLA-mismatched patient as nega-
tive control. For TCRs, corresponding patients, and exact co-
incubation cell numbers, see Table 2 and Supplementary
Table 4. Numbers of cells isolated from tumor or unaffected
mucosa tissues varied between patients due to the size of
surgical specimens. The majority of cells isolated from tissues
were non-lymphocytes (Suppl. Figure 2). All remaining cells
from each patient were used for co-incubation experiments
(Figure 5, Suppl. Figs. 9 + 10) to maximize the chance of
detection of TCR targets in the available specimens. Co-
incubations were done in 96-well plates in a volume of 150
μl RPMI1640 containing 10% FBS for 16 h at 37°C and 5%
CO2.
Fluorescence microscopy
Bright field and GFP fluorescence images were recorded sepa-
rately using a Biorevo BZ-9000E instrument (Keyence)
equipped with an S Plan Fluor ELWD 20x lens and overlaid
for visualization.
HLA-typing
Genomic DNA samples were amplified using GoTaq Long
Range Polymerase (Promega) and HLA-locus-specific primers
(NGSgo workflow, GenDx). Pooling of amplicons, fragmenta-
tion, adapter ligation, DNA clean-up, indexing PCR, second
clean-up, size selection, library pooling, quantification, and
denaturation were performed according to the manufacturer’s
instructions. Sequencing was done on a MiSeq instrument
(Illumina) using 300 cycle kits (151 base pairs, paired-end
sequencing). Data were analyzed with NGSengine software
(GenDx).
Data accessibility
Single cell sequencing data have been made publicly available
(DDBJ/EMBL/GenBank accession KCPL00000000, first ver-
sion KCPL01000000). TCRβ repertoire sequencing data are
available online (suppl_online_table_1.xlsx). Single cell cyto-
kine and transcription factor sequencing data along with the
corresponding FACS index sort data are available online
(suppl_online_table_2.xls).
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